Van Leeuwen & Company’s AbbVie ABBV Stock Holding History

Van Leeuwen & Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,155	Closed	-$3.05M	–	77
2023 Q1	$3.05M	Buy	+19,155	New	+$2.93M	2.05%	17
2021 Q3	–	Sell	-19,683	Closed	-$2.25M	–	67
2021 Q2	$2.25M	Buy	+19,683	New	+$2.22M	1.33%	27
2019 Q1	–	Sell	-3,296	Closed	-$304K	–	76
2018 Q4	$304K	Buy	3,296 +130	+4%	+$11.4K	0.3%	63
2018 Q3	$299K	Buy	+3,166	New	+$300K	0.28%	68

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Van Leeuwen & Company's ABBV Position: Q2 2023 in Review

Van Leeuwen & Company sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 19,155 shares — an estimated $3.05M sold.

Van Leeuwen & Company first reported a position in ABBV in Q3 2018 and held it in 4 quarters. The position peaked at $3.05M in Q1 2023. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

Van Leeuwen & Company reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
Van Leeuwen & Company sold 19,155 AbbVie shares in Q2 2023, an estimated $3.05M.
Van Leeuwen & Company first reported a position in AbbVie in Q3 2018 and held it in 4 quarters.
Van Leeuwen & Company's AbbVie position peaked at $3.05M in Q1 2023.
3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Van Leeuwen & Company's 13F filing for Q2 2023, filed 7 Aug 2023.